Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy of trilostane for the treatment of equine Cushing's syndrome

Efficacy of trilostane for the treatment of equine Cushing's syndrome Summary Reasons for performing study: Trilostane, a competitive 3‐beta hydroxysteroid dehydrogenase inhibitor, has been used successfully to control clinical signs and cortisol excess in canine pituitary dependent hyperadrenocorticism Objectives: Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety. Methods: Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4–1 mg/kg (mean 0.5 mg/kg) trilostane once daily. Results: Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 ± 53.0 nmol/l) and after (130 ± 46.1 nmol/l) trilostane. Conclusions: Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration. Potential relevance: Trilostane may be a useful therapy for the treatment of ECS. Further work comparing the effects of trilostane and pergolide is warranted. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Equine Veterinary Journal Wiley

Efficacy of trilostane for the treatment of equine Cushing's syndrome

Equine Veterinary Journal , Volume 35 (4) – Jun 1, 2003

Loading next page...
 
/lp/wiley/efficacy-of-trilostane-for-the-treatment-of-equine-cushing-s-syndrome-l9aDfSnd60

References (17)

Publisher
Wiley
Copyright
2003 EVJ Ltd
ISSN
0425-1644
eISSN
2042-3306
DOI
10.2746/042516403776014271
Publisher site
See Article on Publisher Site

Abstract

Summary Reasons for performing study: Trilostane, a competitive 3‐beta hydroxysteroid dehydrogenase inhibitor, has been used successfully to control clinical signs and cortisol excess in canine pituitary dependent hyperadrenocorticism Objectives: Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety. Methods: Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4–1 mg/kg (mean 0.5 mg/kg) trilostane once daily. Results: Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 ± 53.0 nmol/l) and after (130 ± 46.1 nmol/l) trilostane. Conclusions: Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration. Potential relevance: Trilostane may be a useful therapy for the treatment of ECS. Further work comparing the effects of trilostane and pergolide is warranted.

Journal

Equine Veterinary JournalWiley

Published: Jun 1, 2003

There are no references for this article.